Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies

International Journal of Cancer

Volumn 126, Issue 1, 2010, Pages 297-301

  Chan, Paul K S ^a   Chang, Alexander R ^b   Yu, Mei Y ^a   Li, Wai Hon ^c   Chan, May Y M ^c   Yeung, Apple C M ^a   Cheung, Tak Hong ^a   Yau, Tat Nga ^c   Wong, Sze Man ^c   Yau, Ching Wai ^c   Ng, Ho Keung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Age; Cervical cancer; Cervical intraepithelial neoplasia; Chinese; Hong Kong; Human papillomavirus; Pap smear; Screening

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INVASION; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ADULT; AGE FACTORS; AGED; CHINA; FEMALE; HEALTH POLICY; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 73449109539     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24731     Document Type: Article

References (26)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189: 12-19.
2. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
3. De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9.
4. Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer 2008;123:1344-49.
5. Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodríguez AC, Bratti MC, Hildesheim A, Wacholder S, Long LR, Neve L, Pfeiffer R, Burk RD. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res 2006;66:1218-24.
6. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, Rodriguez AC, Hutchinson ML, Bratti MC, Hildesheim A, Morales J, Alfaro M, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66: 10112-19.
7. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
8. Hong Kong Cancer Registry. Hospital Authority. Fast Stats on Cervical Cancer 2006. Available at: http://www3.ha.org.hk/cancereg/e-cx.pdf. Retrieved January 23, 2009.
9. Chan PK, Luk AC, Luk TN, Lee KF, Cheung JL, Ho KM, Lo KK. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol 2009; 44:111-14.
10. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348: 518-27.
11. International Agency for Research on Cancer (IARC) working group. Human papillomaviruses. In: Jane Mitchell, ed. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 90, Lyon: IARC Press, 2007;1-670.
12. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE. WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
13. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
14. Sawaya GF, Sung HY, Kearney KA, Miller M, Kinney W, Hiatt RA, Mandelblatt J. Advancing age and cervical cancer screening and prognosis. J Am Geriatr Soc 2001;49:1499-504.
15. Kim JJ, Leung GM, Woo PP, Goldie SJ. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. J Public Health 2004;26:130-7.
16. Adab P, Mcghee SM, Yanova J, Wong CM, Hedley AJ. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. Med Care 2004;42:600-9.
17. The University of Hong Kong.Population Health Survey Report. Hong Kong, People's Republic of China: Department of Health, Government of the Hong Kong Special Administrative Region, 2005.
18. Bosch FX, De Sanjosé S. Chapter 1: human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr 2003;3-13.
19. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005;113:1005-9.
20. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360:1385-94.
21. Zhao C, Austin RM. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer 2008;114:242-8.
22. Zhao C, Austin RM. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol Oncol 2007;107:231-5.
23. Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine 2008;26: K42-52.
24. Hong Kong Cancer Registry. Hospital Authority. Available at: http://www3.ha.org.hk/cancereg/default.asp. Retrieved 23 January 2009.
25. Ashley DJ. The biological status of carcinoma in-situ of the uterine cervix. J Obstet Gynaecol Br Common 1966;73: 372-81.
26. Kashgarian M, Dunn JE. The duration of intraepithelial and preclinical squamous cell carcinoma of the uterine cervix. Am J Epidemiol 1970;92:211-22.